Archive - RAS Dialogue
- Combination Screens for Cancer Vulnerabilities: A Conversation with Kris Wood
Cancers driven by mutant KRAS are difficult to treat. Combining genetic screens with drugs that work downstream of mutant KRAS reveals cellular adaptations to uncontrolled growth that may be targeted.
- Conversation with Elizabeth Jaffee: An Immuno-Oncology Update
Immunotherapy is becoming part of the "standard of care" for many cancer patients. Elizabeth Jaffee describes how we got here and where we need to go in the future.
- Don't Miss the Connection: The Role of RAF1 and ROKα in RAS-Driven Cancers
Cancer caused by a mutant KRAS gene is dependent on the presence of one of its downstream effectors, RAF1 (aka CRAF), but not on ARAF or BRAF. Kinase-independent interaction of RAF1 with ROKα accounts for at least some of this dependence.
- Genetic Ablation of KRAS in Pancreas Cancer: When an Essential Oncogene Isn’t
Of all cancers, pancreatic cancers are most dependent on mutant KRAS. However, many pancreatic cancer cell lines survive loss of their mutant KRAS genes. The adaptations these lines make provide opportunities for treating these deadly cancers.